They used a proprietary in-house cancer genome analysis system and assessed the type and frequencies of gene mutations based on TMB, MSI, and tumor site. 14 tumors were classified as TMB-high.

It will also develop a plasma-based test using the GuardantOMNI assay, which scores tumor mutational burden (TMB) to predict responses to AstraZeneca’s immunotherapies and targeted drugs.